As of yesterday, the Therapeutic Goods Administration approved a new cancer drug which will help reduce the chance of relapse for those with early stages of HER2 - positive breast cancer.
Breast Cancer Research Centre oncologist Professor Arlene Chan says this medication, Nerlynx, is the only drug which has shown to reduce the risk of recurrence after chemotherapy and trastuzumab.
Trials have shown that this oral treatment reduces women’s five-year risk of the disease re-emerging or death by 42 percent.